Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project.
暂无分享,去创建一个
L. Niskanen | T. Hedner | J. Lanke | L. Hansson | L. Hansson | A. Niklason
[1] Bruce H. R. Wolffenbuttel,et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.
[2] S. Yusuf,et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[3] S. Yusuf,et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[4] C. Bulpitt,et al. Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension , 1999 .
[5] L. Niskanen,et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.
[6] L. Niskanen,et al. Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis. , 1998, Diabetes care.
[7] Philip D. Harvey,et al. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39 , 1998, BMJ.
[8] Philip D. Harvey,et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.
[9] R. Holman,et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .
[10] Joël Ménard,et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.
[11] M. Pahor,et al. Outcome Results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in Patients With Hypertension and NIDDM , 1998, Diabetes Care.
[12] R. Schrier,et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. , 1998, The New England journal of medicine.
[13] L. Niskanen,et al. The Captopril Prevention Project (CAPPP) in hypertension--baseline data and current status. , 1997, Blood pressure.
[14] A. Levey,et al. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. , 1997, Annals of internal medicine.
[15] B. Nordestgaard,et al. ACE Gene Polymorphism as a Risk Factor for Ischemic Cerebrovascular Disease , 1997, Annals of Internal Medicine.
[16] HelmutDrexler,et al. Role of Bradykinin in Mediating Vascular Effects of Angiotensin-Converting Enzyme Inhibitors in Humans , 1997 .
[17] B. Davis,et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. , 1996, JAMA.
[18] R. Schmieder,et al. Reversal of Left Ventricular Hypertrophy in Essential Hypertension: A Meta-analysis of Randomized Double-blind Studies , 1996 .
[19] B. Strauer,et al. Improvement of coronary flow reserve after long-term therapy with enalapril. , 1996, Hypertension.
[20] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.
[21] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .
[22] E. H. Blaine,et al. Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits. , 1993, The Journal of clinical investigation.
[23] Na Na. Hypertension in Diabetes Study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients: The Hypertension in Diabetes Study Group , 1993, Journal of hypertension.
[24] J. Neaton,et al. Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial , 1993, Diabetes Care.
[25] E. J. Brown,et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.
[26] G. Mancia,et al. Sympathomoderating influence of benazepril in essential hypertension , 1992, Journal of hypertension.
[27] C. Berne,et al. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. , 1989, The New England journal of medicine.
[28] G. Klerman,et al. The effects of antihypertensive therapy on the quality of life. , 1986, The New England journal of medicine.
[29] P. McNamara,et al. Morbidity and Mortality in Diabetics In the Framingham Population: Sixteen Year Follow-up Study , 1974, Diabetes.
[30] Teven,et al. MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .
[31] C. Bulpitt,et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. , 1999, The New England journal of medicine.
[32] Bruce Neal,et al. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. , 1999, Journal of hypertension.
[33] Detection. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) , 1997 .
[34] K. Pennert,et al. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. , 1992, American journal of hypertension.
[35] T. Hedner,et al. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. , 1992, Blood pressure.
[36] W. de Oliveira Júnior. [The effects of antihypertensive therapy on the quality of life]. , 1989, Arquivos brasileiros de cardiologia.